| Literature DB >> 29730017 |
Marlène C H Hekman1, Mark Rijpkema2, Erik H Aarntzen2, Sasja F Mulder3, Johan F Langenhuijsen4, Egbert Oosterwijk4, Otto C Boerman2, Wim J G Oyen5, Peter F A Mulders4.
Abstract
Based on the high expression of carbonic anhydrase IX (CAIX) in 95% of clear cell renal cell carcinoma (ccRCC), the anti-CAIX monoclonal antibody girentuximab can be used for the detection of ccRCC. This clinical study explores the value of 89Zr-labeled girentuximab positron emission tomography/computed tomography (PET/CT) imaging in diagnostic challenges regarding ccRCC. PET/CT imaging was performed 4 or 5 d after injection of 89Zr-girentuximab in patients with a primary renal mass (n=16) or a history of ccRCC (n=14). Scans were used for decision making (surgery/active surveillance) in case of indistinct renal masses. All resected PET-positive primary lesions proved to be ccRCC, while no lesion progression was seen in PET-negative masses. In patients suspected of recurrent/metastatic ccRCC, PET/CT with 89Zr-girentuximab was useful to confirm or exclude ccRCC, evaluate the extent of the disease, and differentiate from other cancers. In this group, 89Zr-girentuximab PET/CT resulted in a major change in clinical management in five patients (36%), while in three patients (21%) repeat biopsies could be avoided. We conclude that 89Zr-girentuximab PET/CT is a valuable diagnostic tool that can guide clinical decision making in case of diagnostic dilemmas concerning ccRCC suspicion. PATIENTEntities:
Keywords: Girentuximab; Positron emission tomography/computed tomography imaging; Renal cell carcinoma; Zirconium-89
Mesh：
Substances：
Year: 2018 PMID： 29730017 DOI： 10.1016/j.eururo.2018.04.026
Source DB: PubMed Journal: Eur Urol ISSN： 0302-2838 Impact factor: 20.096